Published in:
Open Access 01-12-2022 | Erythropoietin | Research
Erythropoietin in Acute Kidney Injury (EAKI): a pragmatic randomized clinical trial
Published in: BMC Nephrology | Issue 1/2022
Login to get accessAbstract
Background
Treatment with erythropoietin is well established for anemia in chronic kidney disease patients but not well studied in acute kidney injury.
Methods
This is a multicenter, randomized, pragmatic controlled clinical trial. It included 134 hospitalized patients with anemia defined as hemoglobin < 11 g/dL and acute kidney injury defined as an increase of serum creatinine of ≥ 0.3 mg/dL within 48 h or 1.5 times baseline. One arm received recombinant human erythropoietin 4000 UI subcutaneously every other day (intervention; n = 67) and the second received standard of care (control; n = 67) during the hospitalization until discharge or death. The primary outcome was the need for transfusion; secondary outcomes were death, renal recovery, need for dialysis.
Results
There was no statistically significant difference in transfusion need (RR = 1.05, 95%CI 0.65,1.68; p = 0.855), in renal recovery full or partial (RR = 0.96, 95%CI 0.81,1.15; p = 0.671), in need for dialysis (RR = 11.00, 95%CI 0.62, 195.08; p = 0.102) or in death (RR = 1.43, 95%CI 0.58,3.53; p = 0.440) between the erythropoietin and the control group.
Conclusions
Erythropoietin treatment had no impact on transfusions, renal recovery or mortality in acute kidney injury patients with anemia.
The trial was registered on ClinicalTrials.gov (NCT03401710, 17/01/2018).